GlassScriptPhysician profile
Sharman A Moore
NPI 1437150687
$3,443.86
in general payments reported to CMS, 2019-2025
32 companies · $1,082 in 2025
The $1,082 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26.77 · 2021: $267 · 2022: $198 · 2023: $459 · 2024: $1,411 · 2025: $1,082.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,944 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,943.80 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $533.45 | 2022-2025 | |
| Lilly USA, LLC | $446.61 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $442.65 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $284.75 | 2023-2025 | |
| Abbott Laboratories | $183.33 | 2024-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $172.64 | 2021-2025 | Airsupra, Farxiga |
| Otsuka America Pharmaceutical, INC. | $161.03 | 2023-2025 | Rexulti, Nuedexta |
| Lundbeck LLC | $138.65 | 2023-2025 | Rexulti, Vyepti |
| Biohaven Pharmaceuticals, INC. | $134.56 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $92.37 | 2024-2025 | Xifaxan, Trulance |
| Daiichi Sankyo INC. | $74.51 | 2023-2024 | Injectafer |
| Glaxosmithkline, LLC. | $74.46 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Amgen INC. | $74.13 | 2024-2025 | Otezla, Repatha, Repatha |
| Exact Sciences Corporation | $60.42 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Phathom Pharmaceuticals, INC. | $59.81 | 2024-2025 | Voquezna |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $51.02 | 2024-2025 | Xyosted |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $50.72 | 2025 | Caplyta |
| Kowa Pharmaceuticals America, INC. | $45.42 | 2024-2025 | Zoryve |
| Teva Pharmaceuticals USA, INC. | $40.62 | 2023-2024 | Austedo Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.99 | 2021-2023 | |
| Idorsia Pharmaceuticals US INC | $34.52 | 2022-2025 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $32.94 | 2023-2025 | |
| Sanofi Pasteur INC. | $30.69 | 2019-2022 | |
| Acella Pharmaceuticals, LLC | $26.03 | 2025 | NP Thyroid 60 |
| Vanda Pharmaceuticals INC. | $25.83 | 2024 | Fanapt |
| Mayne Pharma Commercial LLC | $23.42 | 2023 | |
| Inspire Medical Systems, INC. | $22.61 | 2025 | Inspire |
| Arbor Pharmaceuticals, INC. | $19.08 | 2021 | |
| Astellas Pharma US INC | $18.64 | 2024 | Veozah |
| Ascensia Diabetes Care US INC. | $17.95 | 2024 | |
| Eisai INC. | $17.56 | 2022 | |
| Vapotherm INC | $15.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharman Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.